Insulin Degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba. It is administered via subcutaneous injection once daily to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours, making it a once-daily basal insulin, that is one that provides a base insulin level, as opposed to the fast and short acting bolus insulins.
- Type 1 Diabetes Mellitus: The recommended starting dose of Tresiba (insulin degludec), for patients who have never used insulin, is approximately one-third to one-half of the total daily insulin dose. Your doctor will explain how to divide the number of units throughout the day.
- Type 2 Diabetes Mellitus: The recommended starting dose of Tresiba (insulin degludec), for patients who have never used insulin, is 10 units once daily.
- Starting Dose in Patients Already on Insulin Therapy for Type 1 and Type 2 Diabetes Mellitus: Insulin degludec will be initiated at the same unit dose as the total daily long or intermediate-acting insulin unit dose.